TYTakahiro Yamada

Takahiro Yamada

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Takahiro Yamada has a total of 562 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • A nationwide survey on attitudes of obstetricians and gynecologists toward comprehensive prenatal genetic testing in Japan

    by Yuka Shibata, Takahiro Yamada, Nahoko Shirato, Akihiko Sekizawa, Aiko Sasaki, Kenichiro Hata, Yuko Masuzawa, Toshiyuki Yamamoto, Hiroshi Yoshihashi, Kanako Koike Fukushima, et al.

  • Open Access

    A novel truncating FBN1 variant in a family with Marfan syndrome

    by Yuka Ito, Hiroshi Suzumura, Yuko Tanaka, George Imataka, Shujiro Hayashi, Yoshimasa Kawarai, Hiroko Susaka, Miyuki Muramatsu, Hiromi Yuasa, Wakana Soeda, et al.

    Marfan syndrome is caused by pathogenic variants in FBN1 . We identified a novel heterozygous frameshift variant in FBN1 (NM_000138.5: c.6784_6787del, NP_000129.3:p.(Gln2262TrpfsTer28)) in an adult male with severe cardiovascular manifestations. The variant was absent from population databases and fulfilled PVS1 and PM2 criteria. This finding expands the mutational and phenotypic spectrum of FBN1 and highlights the clinical utility of genetic testing in family-based clinical management of Marfan syndrome.

  • Two-decade trends in prenatal genetic testing in Japan

    by Aiko Sasaki, Takahiro Yamada, Haruhiko Sago, Nahoko Shirato, Akihiko Sekizawa, Kenichiro Hata, Hideaki Masuzaki, Yuko Masuzawa, Toshiyuki Yamamoto, Hiroshi Yoshihashi, et al.

    Prenatal genetic testing in Japan has undergone major changes over the past 2 decades. Maternal serum screening (MSS), amniocentesis (AC), and chorionic villus sampling (CVS) have been the principal tools used to identify fetal chromosomal abnormalities. Recently, non-invasive prenatal testing (NIPT) has reshaped clinical decision-making. However, updated national-level data capturing trends in conventional prenatal testing methods are limited. We aimed to assess the current landscape of prenatal genetic testing in Japan. To update the national data, we compiled test volumes from five major high-volume laboratories that analysed prenatal genetic tests and conducted a supplemental nationwide questionnaire-based survey on ultrasound (US)-only screening between 2020 and 2023. Over this period, MSS declined from 34,887 cases in 2018 to 25,553 in 2023, AC from 16,454 in 2014 to 5620 in 2023, and CVS from 2149 in 2015 to 1167 in 2023, whereas US-only screening increased slightly to >10,000 cases annually. The chromosomal abnormality detection rate among AC cases increased from 8% during 2006–2014 to 20.0% in 2023, with trisomy 21 comprising 43.6% of the cases. During the same period, the proportion of mothers aged ≥35 years increased from 14.0% in 2003 to 30.4% in 2023, whereas the proportion of national live births decreased by 35.3%. Thus, declining test volumes cannot be attributed solely to demographic changes but also reflect the influence of NIPT uptake, improved pretest risk stratification, and changing reproductive decision-making supported by expanding genetic counselling. This study provides foundational data for future prenatal genetic testing practices and policies in Japan.


  • Open Access

    A Nationwide Survey Investigating the Current Status of Genetic Counseling in Newborn Screening in Japan

    by Eri Sakai, Takahiro Yamada, Takashi Hamazaki, Go Tajima, Toshiyuki Seto

    Following Newborn Screening (NBS), parents receiving positive results experience various psychosocial effects upon learning their child’s genetic information or unexpected findings. These factors warrant careful consideration. The Japanese Medical Association’s Guidelines for Genetic Testing and Diagnosis in Medical Care highlight the importance of genetic counseling (GC) in NBS; however, its current implementation status remains unclear. This study aimed to determine current approaches to GC following positive NBS results in Japan. A questionnaire was conducted with pediatric metabolic specialists responsible for treating individuals who screen positive through NBS results to evaluate GC implementation and their views on its provision. GC was provided at most referral centers for NBS (although not routinely at approximately half of the facilities). In over 70% of cases, GC was performed by a metabolic specialist, regardless of clinical geneticist certification. Furthermore, some metabolic specialists may be reluctant to provide GC due to limited understanding or time constraints. Raising awareness that all parents are eligible for GC, regardless of their child’s diagnosis or health status, is essential. In addition, a GC system incorporating multidisciplinary and multidepartmental collaboration is important for the multifaceted support of patients and families.

  • Open Access

    A Nationwide Survey Investigating the Current Status of Genetic Counseling in Newborn Screening

    by Eri Sakai, Takahiro Yamada, Takashi Hamazaki, Go Tajima, Toshiyuki Seto

    In Newborn Screening (NBS), parents receiving positive results experience various psychosocial effects upon learning their child’s genetic information or unexpected findings. These factors warrant careful consideration. The Japanese Medical Association’s Guidelines for Genetic Testing and Diagnosis in Medical Care highlight the importance of genetic counseling (GC) in NBS; however, its current implementation status remains unclear. This study aimed to determine the current GC status among individuals with positive NBS results in Japan. A questionnaire survey was conducted with pediatric metabolic specialists responsible for treating individuals who screen positive through NBS results to evaluate GC implementation and their views on its provision. GC was provided at most referral center for NBS (although not routine performance at approximately half of the facilities). In over 70% of cases, GC was performed by a metabolic specialist, regardless of clinical geneticist certification. Furthermore, some metabolic specialists may be reluctant to provide GC due to limited understanding or time constraints. Raising awareness that all parents are eligible for GC, regardless of their child’s diagnosis or health status, is essential. In addition, a GC system incorporating multidisciplinary and multidepartmental collaboration is important for the multifaceted support of patients and families.


  • Open Access

    Large Cervical Varices: A Key Risk Factor for Hemorrhage in Placenta Previa

    by Akio Kamiya, Takahiro Yamada, Aya Yoshida, Shuhei Nishibata, Kaede Oku, Mamoru Morikawa, Hidetaka Okada

    Objectives: The primary objective of this study was to determine whether the volume of cervical varices, quantified by magnetic resonance imaging (MRI), predicts massive intraoperative blood loss in placenta previa. The secondary objective was to examine the relationship between cervical varices volume and placental location, sponge-like findings on transvaginal ultrasound (TVUS), and active lower uterine segment bleeding. Design: A retrospective cohort study was conducted. Participants/Materials, Setting, Methods: This study included 98 individuals with singleton pregnancies and placenta previa who underwent prenatal MRI and cesarean section at a tertiary care center in Japan between April 2012 and March 2021. MRI was performed around 34 weeks of gestation as part of routine placenta accreta spectrum (PAS) screening. Cervical varices were defined as high-signal vascular structures located within the cervix and lower uterine segment on sagittal T2-weighted MRI. Their volume was manually calculated as an approximate cervical varices volume (aVCV). Receiver operating characteristic (ROC) analysis was used to determine the optimal aVCV cutoff for predicting massive blood loss (defined as ≥1,500 mL). Logistic regression was used to assess independent predictors of bleeding. A subgroup analysis was conducted among patients with posterior placenta previa without PAS. Results: Cervical varices were detected by MRI in 94.9% of cases. ROC analysis identified 36.0 cm3 as the optimal aVCV cutoff (AUC: 0.63), with a specificity of 86.2% and positive predictive value of 75.9%. Large cervical varices (aVCV >36.0 cm3) were significantly associated with massive bleeding (adjusted odds ratio: 9.44; 95% CI: 3.11–28.7). They also correlated with sponge-like findings on TVUS and posterior placental location but were smaller in cases with anterior placenta or PAS despite high bleeding volumes. Active bleeding from the lower uterine segment was more common in the large aVCV group and was associated with massive hemorrhage in non-PAS cases. In a subgroup of patients with posterior placenta previa without PAS (n = 43), predictive performance improved (AUC: 0.72; specificity: 95.8%; odds ratio: 9.53; 95% CI: 2.19–41.4). Conclusion: Large cervical varices are an independent predictor of massive blood loss in placenta previa, particularly in posterior previa without PAS. Recognition of cervical venous enlargement as a core hemorrhagic risk factor may improve preoperative preparedness and promote broader efforts to refine diagnostic approaches.


  • Familial Alveolar Capillary Dysplasia With Misalignment of Pulmonary Veins Caused by Paternal FOXF1 Upstream Enhancer Deletion: A Case Report

    by Hidenori Kawasaki, Kazuhiko Nakabayashi, Masahiko Ikeda, Tetsuo Onda, Seiichi Tomotaki, Masako Torishima, Akiko Saito, Hirofumi Ohashi, Sachiko Minamiguchi, Kenichiro Hata, et al.

    Alveolar capillary dysplasia with misalignment of pulmonary veins (ACDMPV) is a lethal disease characterized by severe respiratory distress and pulmonary hypertension during the neonatal period, which is seldom diagnosed prenatally. Ten percent of ACDMPV cases are familial and caused by single nucleotide or copy‐number variants in FOXF1 or the FOXF1 enhancer in an autosomal dominant manner. Here, we report a familial case of paternal FOXF1 upstream enhancer deletion, detected as somatic mosaicism in his blood specimen. A 37‐ and 35‐year‐old couple had four children. The first, third, and fourth children suffered from ACDMPV that led to neonatal death. In this case, the first child was misdiagnosed with meconium aspiration syndrome, and the diagnosis of ACDMPV was first made after the autopsy of the third child. The option of preimplantation or prenatal genetic testing did not exist during the pregnancy of the fourth child, as the complex genetic basis became clear only after the death of the fourth child.


  • Nationwide survey of the secondary findings in cancer genomic profiling: survey including liquid biopsy

    by Saki Shimada, Takahiro Yamada, Akari Minamoto, Manami Matsukawa, Ichiro Yabe, Hiroshi Tada, Katsutoshi Oda, Arisa Ueki, Satomi Higashigawa, Maki Morikawa, et al.


  • Identification of a novel LFNG variant in a Chinese fetus with spondylocostal dysostosis and a systematic review

    by Lin Wang, Shuji Mizumoto, Ruixue Zhang, Yuqi Zhang, Yuan Liu, Wenjing Cheng, Xin Li, Min Dan, Chunyan Zhang, Xinru Gao, et al.

    Spondylocostal dysostosis (SCDO) encompasses a group of skeletal disorders characterized by multiple segmentation defects in the vertebrae and ribs. SCDO has a complex genetic etiology. This study aimed to analyze and identify pathogenic variants in a fetus with SCDO. Copy number variant sequencing and whole exome sequencing were performed on a Chinese fetus with SCDO, followed by bioinformatics analyses, in vitro functional assays and a systematic review on the reported SCDO cases with LFNG pathogenic variants. Ultrasound examinations in utero exhibited that the fetus had vertebral malformation, scoliosis and tethered cord, but rib malformation was not evident. We found a novel homozygous variant (c.1078 C > T, p.R360C) within the last exon of LFNG. The variant was predicted to cause loss of function of LFNG by in silico prediction tools, which was confirmed by an in vitro assay of LFNG enzyme activity. The systematic review listed a total of 20 variants of LFNG in SCDO. The mutational spectrum spans across all exons of LFNG except the last one. This study reported the first Chinese case of LFNG-related SCDO, revealing the prenatal phenotypes and expanding the mutational spectrum of the disorder.


  • Difficulties in disclosing secondary findings by facilities performing comprehensive germline genetic testing for rare diseases in Japan

    by Kana Hiromoto, Takahiro Yamada, Mio Tsuchiya, Hiroshi Kawame, Eiji Nanba, Yuichi Goto, Shinji Kosugi

    In Japan, a limited number of laboratories perform comprehensive genetic testing for rare diseases; this study investigated the attitudes of these laboratories toward the disclosure of secondary finding (SF). Following a preliminary survey, we identified laboratories conducting comprehensive genetic testing for participation. Subsequently, an online survey involving 20 selected facilities was conducted. The response rate was 80% (16/20). Of the 14 facilities, 71.4% had SFs. While 42.9% of them had a policy to disclose SFs with clinical utility, only 14.3% actively searched for actionable variants that could be included in the American College of Medical Genetics and Genomics list. Japan was less enthusiastic than the USA regarding SF disclosure. With regard to the reasons for not disclosing SFs, the factors "the thought that participants may have a low desire for SFs" and "uncertainty regarding their wish" were considered more important than in the USA. A content analysis of what was sought as a solution to this difficulty revealed a need to improve databases on pathogenicity and actionability and collect public thoughts on the issue. The factor "to promote entry in research" was not considered a critical reason for disclosing SFs, indicating that the thirst for information was not possibly due to anxiety but rather due to scientific interest. Japanese medical professionals may not be confident that society requires the disclosure of SFs. To improve the environment, it is necessary to survey the public regarding their thoughts on SF disclosure and discuss this issue in society.